Gwendolyn Binder-Scholl

Track

Insider profile

Currently holds a position at Cabaletta Bio Inc

Performance

Overall performance
4.0
Performance over holding periods
4.0
30 days 90 days 120 days
Average return 134% 8.2% 15.1%
Success rate 100% 68% 82%
Transactions
2 100% Buy
34 71% Buy
47 69% Buy
Ranking by holding-period performance

Positions

Position Company Period
Executive Vice President, Science & Technology Cabaletta Bio Inc Feb. 1, 2019 -
Chief Technology Officer Adaptimmune Therapeutics PLC Feb. 9, 2016 - Jan. 31, 2019
Executive Vice President - Adaptimmune LLC Adaptimmune Therapeutics PLC Jan. 1, 2012 - Feb. 9, 2016
Gwendolyn Binder-Scholl's trades of Cabaletta Bio Inc's stock


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date Company B/S Transaction type Nb. shares
Price
Value 		Number of shares Price Value Details
2026-01-21 2026-01-21
B Purchase
36,097 -42.5%
315.77
US$963,707 		36,097 -42.5% 315.77 US$963,707
2024-01-19 2024-01-19
PlS Planned sale
39,788 -41.0%
279.48
US$66,008 		39,788 -41.0% 279.48 US$66,008
2024-01-19 2024-01-19
PlS Planned sale
29,181 -31.7%
138.45
US$20,092 		29,181 -31.7% 138.45 US$20,092
2023-12-19 2023-12-19
PlS Planned sale
3,132 -13.5%
22.22
US$69,593 		3,132 -13.5% 22.22 US$69,593
2023-12-19 2023-12-19
PlS Planned sale
7,868 -25.4%
21.76
US$171,196 		7,868 -25.4% 21.76 US$171,196
2023-11-21 2023-11-20
PlS Planned sale
7,458 -27.2%
18.02
US$134,405 		7,458 -27.2% 18.02 US$134,405
2023-11-21 2023-11-20
PlS Planned sale
3,542 -11.4%
17.39
US$61,608 		3,542 -11.4% 17.39 US$61,608
2023-11-20 2023-11-20
PrS Proposed sale
33,000
17.96
US$592,680 		33,000 17.96 US$592,680
2023-10-19 2023-10-19
PrS Proposed sale
11,000
13.46
US$148,005 		11,000 13.46 US$148,005
2023-10-19 2023-10-19
PlS Planned sale
408 -2.0%
14.28
US$5,825 		408 -2.0% 14.28 US$5,825
2023-10-19 2023-10-19
PlS Planned sale
10,592 -34.2%
13.32
US$141,096 		10,592 -34.2% 13.32 US$141,096
2023-09-20 2023-09-19
PlS Planned sale
700 -3.4%
18.50
US$12,950 		700 -3.4% 18.50 US$12,950
2023-09-20 2023-09-19
PlS Planned sale
10,300 -33.2%
17.50
US$180,270 		10,300 -33.2% 17.50 US$180,270
2023-09-19 2023-09-19
PrS Proposed sale
11,000
18.65
US$205,150 		11,000 18.65 US$205,150
2023-08-22 2023-08-21
PlS Planned sale
300 -1.5%
13.82
US$4,147 		300 -1.5% 13.82 US$4,147
2023-08-22 2023-08-21
PlS Planned sale
10,700 -34.5%
13.41
US$143,436 		10,700 -34.5% 13.41 US$143,436
2023-08-21 2023-08-21
PrS Proposed sale
11,000
12.68
US$139,480 		11,000 12.68 US$139,480
2023-07-19 2023-07-19
PrS Proposed sale
11,000
13.98
US$153,780 		11,000 13.98 US$153,780
2023-07-19 2023-07-19
PlS Planned sale
2,815 -12.3%
14.26
US$40,143 		2,815 -12.3% 14.26 US$40,143
2023-07-19 2023-07-19
PlS Planned sale
8,185 -26.4%
13.67
US$111,879 		8,185 -26.4% 13.67 US$111,879
2023-06-21 2023-06-20
PlS Planned sale
11,000 -35.5%
12.99
US$142,925 		11,000 -35.5% 12.99 US$142,925
2023-06-20 2023-06-20
PrS Proposed sale
11,000
13.12
US$144,320 		11,000 13.12 US$144,320
2023-06-20 2023-06-20
PrS Proposed sale
11,000
13.12
US$144,320 		11,000 13.12 US$144,320
2023-05-19 2023-05-19
PrS Proposed sale
22,000
12.30
US$270,600 		22,000 12.30 US$270,600
2023-05-19 2023-05-19
PlS Planned sale
22,000 -52.4%
11.81
US$259,833 		22,000 -52.4% 11.81 US$259,833
2022-10-18 2022-10-18
B Purchase
20,000 +inf%
0.99
US$19,894 		20,000 +inf% 0.99 US$19,894